Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Commentary

The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is dopamine rather than norepinephrine

Jean-Louis Vincent1 email and Daniel de Backer2

1Head, Department of Intensive Care, Erasme University Hospital, Brussels, Belgium

2Staff member, Department of Intensive Care, Erasme University Hospital, Brussels, Belgium

author email corresponding author email

Critical Care 2003, 7:6-8doi:10.1186/cc1851

Published: 9 December 2002


This article is based upon a presentation at the 31st Annual Congress of the Society of Critical Care Medicine (SCCM), San Diego, California, USA, 26-30 January 2002. The presentation was supported by the International Sepsis Forum (ISF). See related Commentary: http://ccforum.com/content/7/1/3

Abstract

Norepinephrine (noradrenaline) and dopamine are commonly used first-line vasopressor agents in the treatment of patients with septic shock. Recently increasing interest has focused on whether one or other of these agents is superior in terms of improving outcome. Studies have looked particularly at the possible local effects of the vasopressors on splanchnic circulation, because evidence suggests that this area is important in the development and maintenance of septic shock. However, the many studies performed have yielded conflicting data and there is, as yet, little evidence to support one drug over the other in terms of their splanchnic effects. Overall, though, dopamine has many assets that make it a good first-line drug when compared with norepinephrine, and these are highlighted in the present, brief commentary.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.